Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene ...
-- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks -- -- Sequential enrollment planned for OPTIC third and fourth cohorts -- -- Company to host and webcast a discussion with key opinion …